Grail has received a favorable vote from an FDA panel regarding premarket approval for its multi-cancer early detection test. The test is designed to detect cancer-specific methylation patterns and, if detected, predict the cancer signal origin with high accuracy to help guide diagnostic evaluation. While the FDA isn't bound to the committee's decision, it takes them into consideration when making the final regulatory decision. It is expected to make its final ruling on the test's premarket approval in the coming months.